Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron Orodispersible Film for RINV in Pediatric Cancer
NCT07217600Phase 4Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ondansetron in radiotherapy-induced nausea and vomiting (RINV) (2 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Efficacy in preventing vomiting. Started Mar 2025; status: recruiting.
02
Drugs
ondansetron
03
Conditions
radiotherapy-induced nausea and vomiting (RINV)
Beyond the preview
Go deeper on NCT07217600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07217600.